Targeting the senescence-autophagy axis for idiopathic pulmonary fibrosis therapy - PubMed
4 hours ago
- #idiopathic pulmonary fibrosis
- #autophagy
- #senescence
- Idiopathic pulmonary fibrosis (IPF) is a progressive, age-associated lung disease with limited treatment options.
- Current therapies slow decline but do not halt or reverse fibrosis.
- Cellular senescence and impaired autophagy are key factors in IPF pathogenesis.
- Senescent cells secrete proinflammatory and profibrotic mediators, while defective autophagy leads to cellular dysfunction.
- The senescence-autophagy axis involves pathways like TGF-β, AMPK/mTOR, NF-κB, and ROS.
- The review discusses therapeutic strategies, including drug repurposing and next-generation interventions.